376 related articles for article (PubMed ID: 23847328)
1. Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas.
Mayr B; Buslei R; Theodoropoulou M; Stalla GK; Buchfelder M; Schöfl C
Eur J Endocrinol; 2013 Oct; 169(4):391-400. PubMed ID: 23847328
[TBL] [Abstract][Full Text] [Related]
2. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas.
Larkin S; Reddy R; Karavitaki N; Cudlip S; Wass J; Ansorge O
Eur J Endocrinol; 2013 Apr; 168(4):491-9. PubMed ID: 23288882
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas.
Kato M; Inoshita N; Sugiyama T; Tani Y; Shichiri M; Sano T; Yamada S; Hirata Y
Endocr J; 2012; 59(3):221-8. PubMed ID: 22200580
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors.
Shimon I; Yan X; Taylor JE; Weiss MH; Culler MD; Melmed S
J Clin Invest; 1997 Nov; 100(9):2386-92. PubMed ID: 9410919
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Head-to-Head Comparison Between Octreotide and Pasireotide in GH-Secreting Pituitary Adenomas.
Gatto F; Feelders RA; Franck SE; van Koetsveld PM; Dogan F; Kros JM; Neggers SJCMM; van der Lely AJ; Lamberts SWJ; Ferone D; Hofland LJ
J Clin Endocrinol Metab; 2017 Jun; 102(6):2009-2018. PubMed ID: 28323931
[TBL] [Abstract][Full Text] [Related]
6. ZAC1 and SSTR2 are downregulated in non-functioning pituitary adenomas but not in somatotropinomas.
Vieria Neto L; Wildemberg LE; Colli LM; Kasuki L; Marques NV; Moraes AB; Gasparetto EL; Takiya CM; Castro M; Gadelha MR
PLoS One; 2013; 8(10):e77406. PubMed ID: 24098585
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
9. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study.
Iacovazzo D; Carlsen E; Lugli F; Chiloiro S; Piacentini S; Bianchi A; Giampietro A; Mormando M; Clear AJ; Doglietto F; Anile C; Maira G; Lauriola L; Rindi G; Roncaroli F; Pontecorvi A; Korbonits M; De Marinis L
Eur J Endocrinol; 2016 Feb; 174(2):241-50. PubMed ID: 26586796
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience.
Brzana J; Yedinak CG; Gultekin SH; Delashaw JB; Fleseriu M
Pituitary; 2013 Dec; 16(4):490-8. PubMed ID: 23184260
[TBL] [Abstract][Full Text] [Related]
11. Effects of somatostatin on somatotroph adenomas of the human pituitary: An in vitro functional and morphological study.
Asa SL; Felix I; Kovacs K; Ramyar L
Endocr Pathol; 1990 Dec; 1(4):228-235. PubMed ID: 32357614
[TBL] [Abstract][Full Text] [Related]
12. Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro.
Kontogeorgos G; Asa SL; Kovacs K; Smyth HS; Singer W
Acta Endocrinol (Copenh); 1993 Dec; 129(6):565-72. PubMed ID: 7509101
[TBL] [Abstract][Full Text] [Related]
13. Effects of growth hormone-releasing hormone (GHRH) on densely granulated somatotroph adenomas and sparsely granulated somatotroph adenomas in vitro: a morphological and functional investigation.
Kawakita S; Asa SL; Kovacs K
J Endocrinol Invest; 1989; 12(7):443-48. PubMed ID: 2551950
[TBL] [Abstract][Full Text] [Related]
14. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
[TBL] [Abstract][Full Text] [Related]
15. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
Pisarek H; Pawlikowski M; Kunert-Radek J; Winczyk K
Endokrynol Pol; 2010; 61(2):178-81. PubMed ID: 20464704
[TBL] [Abstract][Full Text] [Related]
16. Impact of gsp oncogene on the expression of genes coding for Gsalpha, Pit-1, Gi2alpha, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity.
Barlier A; Pellegrini-Bouiller I; Gunz G; Zamora AJ; Jaquet P; Enjalbert A
J Clin Endocrinol Metab; 1999 Aug; 84(8):2759-65. PubMed ID: 10443675
[TBL] [Abstract][Full Text] [Related]
17. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.
Plöckinger U; Hoffmann U; Geese M; Lupp A; Buchfelder M; Flitsch J; Vajkoczy P; Jakob W; Saeger W; Schulz S; Dohrmann C
Eur J Endocrinol; 2012 Feb; 166(2):223-34. PubMed ID: 22065857
[TBL] [Abstract][Full Text] [Related]
18. Pathological markers of somatotroph pituitary neuroendocrine tumors predicting the response to medical treatment.
Trouillas J; Vasiljevic A; Lapoirie M; Chinezu L; Jouanneau E; Raverot G
Minerva Endocrinol; 2019 Jun; 44(2):129-136. PubMed ID: 30531694
[TBL] [Abstract][Full Text] [Related]
19. Growth hormone (GH) and prolactin (PRL) gene expression and immunoreactivity in GH- and PRL-producing human pituitary adenomas.
Li J; Stefaneanu L; Kovacs K; Horvath E; Smyth HS
Virchows Arch A Pathol Anat Histopathol; 1993; 422(3):193-201. PubMed ID: 8493775
[TBL] [Abstract][Full Text] [Related]
20. Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation.
Syro LV; Sundsbak JL; Scheithauer BW; Toledo RA; Camargo M; Heyer CM; Sekiya T; Uribe H; Escobar JI; Vasquez M; Rotondo F; Toledo SP; Kovacs K; Horvath E; Babovic-Vuksanovic D; Harris PC
Pituitary; 2012 Sep; 15(3):342-9. PubMed ID: 21744088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
